Abstract:Glycogen storage disorders (GSDs) are a group of inherited metabolic disorders characterized by defects in enzymes involved in glycogen metabolism. Deficiencies in enzymes responsible for glycogen breakdown and synthesis can impair mitochondrial function. For instance, in GSD type II (Pompe disease), acid alpha-glucosidase deficiency leads to lysosomal glycogen accumulation, which secondarily impacts mitochondrial function through dysfunctional mitophagy, which disrupts mitochondrial quality control, generating oxidative stress. In GSD type III (Cori disease), the lack of the debranching enzyme causes glycogen accumulation and affects mitochondrial dynamics and biogenesis by disrupting the integrity of muscle fibers. Malfunctional glycogen metabolism can disrupt various cascades, thus causing mitochondrial and cell metabolic dysfunction through various mechanisms. These dysfunctions include altered mitochondrial morphology, impaired oxidative phosphorylation, increased production of reactive oxygen species (ROS), and defective mitophagy. The oxidative burden typical of GSDs compromises mitochondrial integrity and exacerbates the metabolic derangements observed in GSDs. The intertwining of mitochondrial dysfunction and GSDs underscores the complexity of these disorders and has significant clinical implications. GSD patients often present with multisystem manifestations, including hepatomegaly, hypoglycemia, and muscle weakness, which can be exacerbated by mitochondrial impairment. Moreover, mitochondrial dysfunction may contribute to the progression of GSD-related complications, such as cardiomyopathy and neurocognitive deficits. Targeting mitochondrial dysfunction thus represents a promising therapeutic avenue in GSDs. Potential strategies include antioxidants to mitigate oxidative stress, compounds that enhance mitochondrial biogenesis, and gene therapy to correct the underlying mitochondrial enzyme deficiencies. Mitochondrial dysfunction plays a critical role in the pathophysiology of GSDs. Recognizing and addressing this aspect can lead to more comprehensive and effective treatments, improving the quality of life of GSD patients. This review aims to elaborate on the intricate relationship between mitochondrial dysfunction and various types of GSDs. The review presents challenges and treatment options for several GSDs.

Glycogen Storage Disease Manifested As Gout and Myopathy: Three Case Reports and Literature Review

Glycogen storage diseases: An update

Glycogen Storage Diseases: A Brief Review and Update on Clinical Features, Genetic Abnormalities, Pathologic Features, and Treatment

Genetic Analysis and Clinical Assessment of Four Patients with Glycogen Storage Disease Type IIIa in China

Narrative review of glycogen storage disorder type III with a focus on neuromuscular, cardiac and therapeutic aspects

Glycogen storage diseases: Diagnosis, treatment and outcome

Update on glycogen storage disease: primary hepatic involvement

Glycogen storage diseases with liver involvement: a literature review of GSD type 0, IV, VI, IX and XI

Glycogen storage diseases: New perspectives

Expanding the clinicopathological-genetic spectrum of glycogen storage disease type IXd by a Chinese neuromuscular center

Misdiagnosis as steatohepatitis in a family with mild glycogen storage disease type 1a.

Mitochondrial Dysfunction in Glycogen Storage Disorders (GSDs)

Report of 7 cases of glycogen storage disease type VI and type IXa

Three novel SLC37A4 variants in glycogen storage disease type 1b and a literature review

A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III

Glycogen Storage Disease in Adults

Glycogen Storage Disease Type Ⅱ Complicating Pregancy: a Case Report and Literatures Review

[Clinical and Gene Mutation Analysis of Three Children with Late-Onset Glycogen Storage Disease Type Ⅱ with Hypertrophic Cardiomyopathy].

Clinical features of gout in adult patients with type Ia glycogen storage disease: a single-centre retrospective study and a review of literature

[Infant glycogen storage disease type Ⅳ: a clinicopathological and genetic characteristics analysis of five cases]

Genetic analysis and long-term treatment monitoring of 11 children with glycogen storage disease type IIIa